News and Announcements

  • Home
  • News and Announcements

Allegro also announces FDA acceptance of IND for ALG-1007 for dry eye disease, clearing path to initiate Phase 2b/3 U.S. study

Allegro Ophthalmics announced that all primary and secondary endpoints of an ex-U.S. vehicle-controlled study of ALG-1007 topical eye drop in patients with dry eye disease (DED) were met. The results were presented by Eric D. Donnenfeld, M.D., at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS ASOA) Annual Meeting in Las Vegas.

The study authors determined ALG-1007, a fixed combination of 0.6% risuteganib and 0.125% sodium hyaluronate in a vehicle solution, demonstrated the highest efficacy among four study arms (p<.001) comprising various combinations of the solution components. No adverse events, ocular irritation, or prolonged blurring of vision were reported in the study. Compared with patients in the control arms, patients who received ALG-1007 experienced statistically significant better results in tear break-up time, inferior corneal staining, and scores on the dry eye management scale and visual analog scales. Statistical significance versus the control was seen as early as 2 weeks.

The company also announced that the U.S. Food and Drug Administration (FDA) accepted the filing of an Investigational New Drug (IND) application for ALG-1007, paving the way for Phase 2b clinical development in the U.S.

“Allegro is happy to share the results of our second ex-U.S. clinical trial, which continue to suggest that ALG-1007 improves the signs and symptoms of dry eye,” said Vicken Karageozian, M.D., President and CEO of Allegro Ophthalmics. “These results support the development of a U.S.-based phase 2b/3 study. These data, coupled with the FDA’s acceptance of Allegro’s IND application, will allow investigators to collect more data to elucidate our understanding of how ALG-1007 may provide relief to patients with dry eye, a disease that adversely affects millions of people worldwide.”

“I’m very encouraged by the results of this trial, which demonstrated that ALG-1007 had the most robust improvement in signs and symptoms of dry eye compared to the comparator arms,” said Dr. Donnenfeld, founding partner of Ophthalmic Consultants of Long Island and Clinical Professor of Ophthalmology at NYU. “The components in ALG-1007 appear to have synergistic effects. It should be emphasized that no adverse events, ocular irritation, or prolonged blurred vision were reported in the study—an impressive finding.”

The prospective, randomized, double-masked, vehicle-controlled study was conducted in Armenia. Researchers randomly assigned patients to one of four arms (64 eyes total; 16 eyes per arm): vehicle; vehicle and 0.125% sodium hyaluronate; vehicle and 0.6% risuteganib; and ALG-1007, which contains vehicle, 0.125% sodium hyaluronate, and 0.6% risuteganib. Patients struggling with dry eye signs and symptoms for at least 6 months received 1 drop twice daily for 12 weeks, at which point data were collected and analyzed. Exclusion criteria included history of ocular herpetic keratitis, LASIK surgery, or use of glaucoma medication; any ocular surgery in the past 6 months; and current use of DED therapy.

Have a business Query? Let's Talk.

Email : info@sciinovgroup.com or Call : USA: +1 732 526 1166
India: +91 7997224449

Get The Latest Updates

Signup For Newsletter

(c) 2021 Sciinov Group - All rights reserved.